Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients

Murphy, Gerald P.; Maguire, Robert T.; Rogers, Barbara; Partin, Alan W.; Nelp, Wil B.; Troychak, M.J.; Ragde, Haakon; Kenny, Gerald M.; Barren, Robert J.; Bowes, Victoria; Gregorakis, Alkibiades; Holmes, Eric H.; Boynton, Alton L.

doi:10.1002/(sici)1097-0045(19971201)33:4<281::aid-pros9>3.0.co;2-k

Cited by 49 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that when the PSMA -/PSA + profile decreased in normal prostates, benign prostatic tissue, and primary prostate cancers, the PSMA + /PSAlevel increased from normal to prostate tumor tissues. Generally, researchers support the idea that the amount of PSMA and/or PSA in healthy men is low in the blood and it increases either with age or because of inflammation of prostate gland (prostatitis) or prostatecancer [16,17,21,22,23] To decrease the side effects of any prostate therapy, it is crucial to develop a good screening pattern for preventing the disease. Finding a tumor at an early stage may be easier to treat before it will cause serious symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…[14] To determine the expression of the above-mentioned genes in a protein level, flow cytometric analysis was performed (BD Accuri™ C6 Flow Cytometer, BD Biosciences) . [7,8,15,16,17] The .31) -product of homeobox protein Nanog, oct3/4 -octamer-binding transcription factor 4, sox2 -also known as SRY (sex determining region Y)-box 2 Presentation of the relative expression rates of the three stemness markers as they were analyzed in two different culturing conditions (STEMPRO and DMEM medium) including the same starting population (prostate cancer stem cell-like cells isolated from a prostate patient, stage IV) using 18S rRNA as control. The correlation between DMEM and STEMPRO-cultivated cells was made using the Livak method.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?

Maria¹,

Apostolou²,

Chatziioannou³

et al. 2014

J Can Res Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?

Maria¹,

Apostolou²,

Chatziioannou³

et al. 2014

J Can Res Ther

View full text Add to dashboard Cite

show abstract

“…Previous studies suggest that serum PSMA levels and immune scans may provide prognostically signi®cant information. 3 Histological examination and long-term outcome data are needed to evaluate the prognostic and therapeutic signi®cance of soft tissue uptake in men with clinically localized cancer.…”

Section: Discussionmentioning

confidence: 99%

Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer

Feneley¹,

Jan²,

Granowska³

et al. 2000

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Radioimmunoscintigraphy using a radio-labelled antibody to prostate-speci®c membrane antigen (PSMA) has growing applications as a means of tissuespeci®c imaging based on functional characteristics and complements traditional staging investigations. Clinical applications in men with carcinoma of the prostate are being re®ned, and this study reports outcomes with this technique in our practice. Prostatic immunoscintigraphy scans were performed with In-111 CYT 356 in 49 men with carcinoma of the prostate, obtaining sequential images in two and three dimensions at 10 min, 24 and 48 h. Of the 49 men, 36 had clinically localized cancer, 10 had recurrent disease after radical radiotherapy or radical prostatectomy and three had rising PSA after primary endocrine treatment. Scan ®ndings are discussed in the context of clinical management. Of the 36 men with clinically localized cancer, seven had increased uptake in regional and distant lymph nodes. Of these seven, three were treated with hormone manipulation, two by radical prostatectomy and two by radical radiotherapy. Among 10 patients who had recurrence after radical treatment of the primary tumour, scans showed local recurrence alone in four, and six had regional or distant metastases. Three patients treated with primary hormone manipulation had scans for rising PSA, and of these one had a positive regional node and two had distant soft tissue and bone metastases. In conclusion, prostatic radio-immunoscintigraphy scans highlight tissues involved by prostate cancer, including the prostate, lymph nodes, soft tissues and bone metastases as well as pelvic recurrence. Results may contribute to the clinical management of individual patients, although histological con®rmation may be appropriate when considering alternative treatment. Prostate Cancer and Prostatic Diseases (2000) 3, 47±52.

show abstract

“…Since 1996 there has been a murine monoclonal antibody to PSMA radiolabeled with 111 In, known as [ 111 In]capromab pendetide or ProstaScint™, used to image PCa [177,178]. However, monoclonal antibodies are somewhat cumbersome as imaging agents due to their long circulation times, which cause significant background radioactivity within the blood pool and other non-target tissues.…”

Section: Gcpii As a Therapeutic Targetmentioning

confidence: 99%

Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer

Bařinka

Rojas²,

Slusher³

et al. 2012

CMC

168

175

View full text Add to dashboard Cite

Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highest expression levels found in the nervous and prostatic tissue. Throughout the nervous system, glia-bound GCPII is intimately involved in the neuron-neuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG), the most abundant mammalian peptidic neurotransmitter. The inhibition of the GCPII-controlled NAAG catabolism has been shown to attenuate neurotoxicity associated with enhanced glutamate transmission and GCPII-specific inhibitors demonstrate efficacy in multiple preclinical models including traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, and schizophrenia. The second major area of pharmacological interventions targeting GCPII focuses on prostate carcinoma; GCPII expression levels are highly increased in androgen-independent and metastatic disease. Consequently, the enzyme serves as a potential target for imaging and therapy. This review offers a summary of GCPII structure, physiological functions in healthy tissues, and its association with various pathologies. The review also outlines the development of GCPII-specific small-molecule compounds and their use in preclinical and clinical settings.

show abstract

Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients

Cited by 49 publications

References 19 publications

How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?

How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations?

Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer

Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer

Contact Info

Product

Resources

About